文献速递肝病

纤维化分期是原发性胆汁性胆管炎预后的独立预测因素

Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response.
PubMed 文献 · Aliment Pharmacol Ther · 2019-10-17

该研究在1828例原发性胆汁性胆管炎患者中评估基线肝纤维化分期对无移植生存的预测价值。即使达到生化治疗应答,晚期纤维化患者10年生存率仍较低(76.0%-86.6% vs 94.5%-95.1%)。

要点

  • 基线晚期纤维化(3/4期)是PBC患者无移植生存的独立预测因素。
  • 即使1年生化应答,晚期纤维化患者10年生存率仍低于早期纤维化者。
  • 无创纤维化标志物与组织学分期相关性差,不能替代肝活检分期。

核心结论

  • 纤维化分期可提供超越1年生化治疗应答的预后价值,应纳入PBC患者个体化风险分层。

研究设计与样本

  • 研究纳入1980至2014年间接受肝活检的全球代表性PBC患者队列,共1828例有基线肝活检。
  • 采用Cox比例风险模型评估组织学纤维化分期、1年治疗应答(Toronto/Paris-II标准)及无创纤维化标志物(AAR、APRI、FIB-4)对无移植生存的预测能力。

主要发现

  • 晚期组织学纤维化患者即使达到生化治疗应答,10年生存率仍为76.0%-86.6%,低于早期纤维化者的94.5%-95.1%(取决于所用应答标准)。
  • 无创纤维化标志物与组织学纤维化分期之间相关性较差。

临床怎么用

  • 在PBC患者风险分层中应考虑肝纤维化分期,而不仅依赖生化治疗应答。
  • 纤维化分期有助于识别可能从新疗法中获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fibrosis stage predicts prognosis in patients with chronic liver disease independent of aetiology, although its precise role in risk stratification in patients with primary biliary cholangitis (PBC) remains undefined. AIM: To assess the utility of baseline fibrosis stage in predicting long-term outcomes in the context of biochemical risk stratification METHODS: In a large and globally representative cohort of patients with PBC, liver biopsies performed from 1980 to 2014 were evaluated. The predictive ability of histologic fibrosis stage in addition to treatment response at 1 year (Toronto/Paris-II criteria), as well as non-invasive markers of fibrosis (AST/ALT ratio [AAR], AST to platelet ratio index [APRI], FIB-4), for transplant-free survival was assessed with Cox proportional-hazards models. RESULTS: There were 1828 patients with baseline liver biopsy. Advanced histologic fibrosis (stage 3/4) was an independent predictor of survival in addition to non-invasive measures of fibrosis with the hazard ratios ranging from 1.59 to 2.73 (P < .001). Patients with advanced histologic fibrosis stage had worse survival despite biochemical treatment response, with a 10-year survival of 76.0%-86.6% compared to 94.5%-95.1% depending on the treatment response criteria used. Poor correlations were observed between non-invasive measures of fibrosis and histologic fibrosis stage. CONCLUSION: Assessment of fibrosis stage grants prognostic value beyond biochemical treatment response at 1 year. This highlights the need to incorporate fibrosis stage in individual risk stratification in patients with PBC, partly to identify those that may derive benefit from novel therapies.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Murillo Perez CF, Hirschfield GM, Corpechot C, et al. Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Aliment Pharmacol Ther. 2019. PMID: 31621931. doi:10.1111/apt.15533

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。